Suttmann, H.; Gleissner, J.; Huebner, A.; Mathes, T.; Baurecht, W.; Krützfeldt, K.; Sweiti, H.; Feyerabend, S.
Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial. Cancers 2020, 12, 2550.
https://doi.org/10.3390/cancers12092550
AMA Style
Suttmann H, Gleissner J, Huebner A, Mathes T, Baurecht W, Krützfeldt K, Sweiti H, Feyerabend S.
Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial. Cancers. 2020; 12(9):2550.
https://doi.org/10.3390/cancers12092550
Chicago/Turabian Style
Suttmann, Henrik, Jochen Gleissner, Andreas Huebner, Tim Mathes, Werner Baurecht, Katrin Krützfeldt, Hussein Sweiti, and Susan Feyerabend.
2020. "Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial" Cancers 12, no. 9: 2550.
https://doi.org/10.3390/cancers12092550
APA Style
Suttmann, H., Gleissner, J., Huebner, A., Mathes, T., Baurecht, W., Krützfeldt, K., Sweiti, H., & Feyerabend, S.
(2020). Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial. Cancers, 12(9), 2550.
https://doi.org/10.3390/cancers12092550